Cargando…

Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core

Pharmaceutical companies with a medical mindset and an empowered Medical Affairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates, so too do expectations. Evidence-based practice, without delay, is...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulford-Smith, Antony, Leah, Emma, Azroyan, Anie, De Abadal, Monica, Loew, David, Hildemann, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898556/
https://www.ncbi.nlm.nih.gov/pubmed/35249212
http://dx.doi.org/10.1007/s40290-022-00419-x
_version_ 1784663681548681216
author Fulford-Smith, Antony
Leah, Emma
Azroyan, Anie
De Abadal, Monica
Loew, David
Hildemann, Steven
author_facet Fulford-Smith, Antony
Leah, Emma
Azroyan, Anie
De Abadal, Monica
Loew, David
Hildemann, Steven
author_sort Fulford-Smith, Antony
collection PubMed
description Pharmaceutical companies with a medical mindset and an empowered Medical Affairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates, so too do expectations. Evidence-based practice, without delay, is expected throughout the development and delivery of medicine, healthcare, and information, and potential sources of evidence are legion. To keep pace and go beyond, to innovate, requires efficiencies. Not the disguised cutbacks of political language, but the collaborative constructive efficiencies of shared learning, forming new evidence bases for further progress. Here, we describe the first year of a medical transformation process at a global mid-sized pharmaceutical company. Beginning with a broad review designed to leverage collective intelligence and focus on meaningful outcomes for patients, this process examined and reshaped the structure, culture, and tools of the medical organization and its interactions within and outside the company. We report the findings of the diagnostic phase, outline the solutions implemented to date, and anticipate the next steps in this dynamic evolving journey.
format Online
Article
Text
id pubmed-8898556
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88985562022-03-07 Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core Fulford-Smith, Antony Leah, Emma Azroyan, Anie De Abadal, Monica Loew, David Hildemann, Steven Pharmaceut Med Current Opinion Pharmaceutical companies with a medical mindset and an empowered Medical Affairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates, so too do expectations. Evidence-based practice, without delay, is expected throughout the development and delivery of medicine, healthcare, and information, and potential sources of evidence are legion. To keep pace and go beyond, to innovate, requires efficiencies. Not the disguised cutbacks of political language, but the collaborative constructive efficiencies of shared learning, forming new evidence bases for further progress. Here, we describe the first year of a medical transformation process at a global mid-sized pharmaceutical company. Beginning with a broad review designed to leverage collective intelligence and focus on meaningful outcomes for patients, this process examined and reshaped the structure, culture, and tools of the medical organization and its interactions within and outside the company. We report the findings of the diagnostic phase, outline the solutions implemented to date, and anticipate the next steps in this dynamic evolving journey. Springer International Publishing 2022-03-06 2022 /pmc/articles/PMC8898556/ /pubmed/35249212 http://dx.doi.org/10.1007/s40290-022-00419-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Current Opinion
Fulford-Smith, Antony
Leah, Emma
Azroyan, Anie
De Abadal, Monica
Loew, David
Hildemann, Steven
Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
title Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
title_full Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
title_fullStr Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
title_full_unstemmed Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
title_short Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
title_sort medical affairs transformation in specialty pharma: next-level collaboration at the core
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898556/
https://www.ncbi.nlm.nih.gov/pubmed/35249212
http://dx.doi.org/10.1007/s40290-022-00419-x
work_keys_str_mv AT fulfordsmithantony medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore
AT leahemma medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore
AT azroyananie medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore
AT deabadalmonica medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore
AT loewdavid medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore
AT hildemannsteven medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore